ENThe Gamma Knife in Germany is stereotactic radiosurgery without knife or incision: many weak gamma beams from cobalt sources cross inside the head, and only where they meet is the dose high enough to act. It treats a small, well-defined target in the skull and is no all-purpose substitute for surgery.
Below: how it compares with CyberKnife and a linear accelerator (linac), what it treats, the treatment day, who decides and which records are needed. If your question is about the tumour, see brain tumour treatment in Germany.
How the Gamma Knife works
A fixed unit holds cobalt-60 sources whose beams meet at a point a few millimetres wide; the head, held by frame or mask, is moved so this focus covers the target. One session usually delivers the whole dose. Outside the target the dose drops steeply, so nearby tissue gets comparatively little.
CyberKnife, a robot-mounted linac, also treats the body (see CyberKnife treatment in Germany); modern linacs also treat stereotactically with masks, but the Gamma Knife only the head. People searching for gamma knife surgery in Germany usually mean this comparison, though the surgery is radiosurgery without an incision. The question is not which machine sounds better but which suits the target’s size and position.
Size is the main limit: lesions beyond a few centimetres are rarely radiosurgery cases. In the guideline of the German radiation oncology society (DEGRO) on breast cancer brain metastases, one session is usual up to 2–2.5 cm, several for larger lesions. Lesion number and earlier irradiation of the area matter too, as doses add up.
What it is used for
The common indications are brain metastases, meningioma, vestibular schwannoma (acoustic neuroma), pituitary adenoma and arteriovenous malformation. Metastases are sharply bounded, and radiosurgery is strongly recommended when there are few. Inoperable or recurrent meningiomas are treated if size and nearby structures allow; small schwannomas are watched or treated, large ones removed. Pituitary adenomas are treated when tumour remains after surgery, malformations especially when deep.
Trigeminal neuralgia is a functional indication: the target is a nerve. The current German Neurological Society guideline in the AWMF register advises considering surgery, radiosurgery included, when drugs fail or are not tolerated. Radiosurgery is an alternative to microvascular decompression for those who fear an operation or face a higher anaesthetic risk, though relief comes later.
Radiosurgery does not remove a mass; it stops or shrinks it over months. If a tumour presses on the brain and pressure must come off now, neurosurgery comes first, radiosurgery may follow. Another precision option is proton therapy in Germany.
How a treatment day runs
The day starts with a planning MRI, sometimes CT or angiography; the head is fixed in a stereotactic frame or thermoplastic mask, depending on device and plan. Frame pins go in under local anaesthetic: pressure, not pain.
Doctors and physicists then outline the target and calculate the dose while the patient waits, often a few hours with a frame. Treatment takes 20 minutes to 2 hours and is painless; only a sedative is needed.
Patients often go home the same day; some stay overnight. Later swelling can cause headache, nausea and drowsiness. The effect shows on MRI months later, and the first scan may show the lesion larger: irradiated tissue swells and inflames in ways hard to tell from growth, so that alone does not mean failure.
Who takes the decision
A tumour board, not the patient alone, weighs the options: neurosurgery, radiation oncology, neuroradiology and, for metastases, medical oncology choose between surgery, radiosurgery, fractionated radiotherapy and drugs (see neurosurgery in Germany). With metastases, current drug therapy counts: if it works in the brain and lesions cause no symptoms, local treatment may wait.
Before answering, a German department needs the MRI on disc, not photographs, the report, histology after any operation, previous radiotherapy records with doses and fields, and current medication; without earlier doses no safe plan is possible.
Partner departments and doctors
Only a few German centres have a Gamma Knife, and AlenMed does not claim a partner hospital has one without written confirmation, so requests go out as questions about method and case, not about a brand.
Radiation oncology partners are the radiotherapy departments of the University Hospital Bonn, a maximum-care hospital, and the University Hospital Ulm, which gives stereotactic and radiosurgical treatment on high-precision linacs, plus a practice in Munich-Pasing that treats some single brain metastases and benign brain tumours stereotactically and arranges care at dedicated centres if they suit better.
A neurosurgeon often assesses whether radiosurgery fits: Professor Bernhard Meyer, director of neurosurgery at the Klinikum rechts der Isar in Munich, whose department covers brain tumour surgery and clinical neuro-oncology; Professor Marcos Tatagiba, medical director of neurosurgery at the University Hospital Tübingen; and Professor Rüdiger Gerlach, a chief physician in neurosurgery and head of the neuro-oncology centre at Helios Klinikum Erfurt, working on brain and skull base tumours, meningiomas and endoscopic skull base surgery. These are examples, not a ranking.
Frequently asked questions
Is Gamma Knife treatment painful?
No: the irradiation is painless and needs no anaesthetic. Fitting the frame is the least pleasant part, but its pins go in under local anaesthetic, so it feels like pressure, not pain. Pin sites may stay red, sensitive or bruised. A mask needs no pins.
Can radiosurgery be repeated?
In some cases, yes. For a metastasis returning at the treated site, the DEGRO guideline considers a second course in selected patients in good condition after more than 12 months. A malformation that has not fully closed is usually re-treated after three to five years of follow-up.
Where should follow-up MRI scans be done?
Scans can be taken at home but are best assessed where treatment was given: German standards call for close follow-up with dedicated imaging, preferably by the treating institution. After radiosurgery for metastases DEGRO suggests MRI every three months, for example. Send files, not photographs.
How AlenMed organises treatment
After first contact, MRI discs and reports are translated and sent to two or three departments, whose replies say whether radiosurgery fits, what the alternative is and how soon to come. For an estimate, see brain tumour treatment cost in Germany.
AlenMed works with 86 partner hospitals in 38 cities and 345 doctors; the company office is in Munich. A coordinator books planning MRI and treatment on consecutive days where possible, interprets at the consultation and consent talk, and collects the treatment report with the imaging schedule.
This material is for information only and is not an offer; a doctor sets the indication at a face-to-face examination.
News on this topic
Charité treats first beta-thalassemia patient with CRISPR
At Berlin Charité, a 19-year-old beta-thalassemia patient became the first in Germany to receive the newly approved CRISPR gene therapy Exagamglogene Autotemcel.
Real-World Breast Cancer Study Confirms High Five-Year Survival Rates in Germany
A landmark study of over 43,000 German patients reveals a five-year invasive disease-free survival rate of 82.9 percent in early hormone receptor-positive breast cancer.
FDA Approves Jülich Diagnostic Radiotracer FET for Brain Tumor Imaging
The FDA approves the diagnostic radiotracer FET (Pixclara®) for evaluating brain gliomas, highlighting decades of neuro-oncology research at Forschungszentrum Jülich.
